[go: up one dir, main page]

ZA974032B - Substituted oxobutyric acids as matrix metalloproteinases inhibitors. - Google Patents

Substituted oxobutyric acids as matrix metalloproteinases inhibitors.

Info

Publication number
ZA974032B
ZA974032B ZA9704032A ZA974032A ZA974032B ZA 974032 B ZA974032 B ZA 974032B ZA 9704032 A ZA9704032 A ZA 9704032A ZA 974032 A ZA974032 A ZA 974032A ZA 974032 B ZA974032 B ZA 974032B
Authority
ZA
South Africa
Prior art keywords
substituted
matrix metalloproteinases
metalloproteinases inhibitors
oxobutyric acids
oxobutyric
Prior art date
Application number
ZA9704032A
Inventor
Brian R Dixon
Jinshan Chen
Michael Van Zandt
David R Brittelli
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA974032B publication Critical patent/ZA974032B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA9704032A 1996-05-15 1997-05-09 Substituted oxobutyric acids as matrix metalloproteinases inhibitors. ZA974032B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
ZA974032B true ZA974032B (en) 1998-02-19

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9704032A ZA974032B (en) 1996-05-15 1997-05-09 Substituted oxobutyric acids as matrix metalloproteinases inhibitors.

Country Status (18)

Country Link
EP (1) EP0912487A1 (en)
JP (1) JP3417951B2 (en)
CN (1) CN1163466C (en)
AR (1) AR007096A1 (en)
AU (1) AU727648B2 (en)
CA (1) CA2253869C (en)
CO (1) CO4990925A1 (en)
HR (1) HRP970246B1 (en)
ID (1) ID20291A (en)
MY (1) MY132470A (en)
PA (1) PA8429401A1 (en)
PE (1) PE65998A1 (en)
SV (1) SV1997000034A (en)
TN (1) TNSN97085A1 (en)
TW (1) TW467892B (en)
WO (1) WO1997043238A1 (en)
YU (1) YU18797A (en)
ZA (1) ZA974032B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP5263548B2 (en) * 2007-08-15 2013-08-14 杏林製薬株式会社 A preventive, suppressive or therapeutic agent for cerebral aneurysms containing ibudilast as an active ingredient
WO2015150362A2 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
CN106661008A (en) 2014-04-03 2017-05-10 拜耳制药股份公司 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69529100T2 (en) * 1994-01-22 2003-07-17 British Biotech Pharmaceuticals Ltd., Cowley metalloproteinase

Also Published As

Publication number Publication date
CA2253869A1 (en) 1997-11-20
CN1225622A (en) 1999-08-11
AR007096A1 (en) 1999-10-13
AU727648B2 (en) 2000-12-21
TW467892B (en) 2001-12-11
JP3417951B2 (en) 2003-06-16
WO1997043238A1 (en) 1997-11-20
SV1997000034A (en) 1999-07-05
CN1163466C (en) 2004-08-25
CA2253869C (en) 2003-04-22
MY132470A (en) 2007-10-31
PA8429401A1 (en) 2000-05-24
PE65998A1 (en) 1998-10-20
AU3121997A (en) 1997-12-05
JPH11509870A (en) 1999-08-31
HRP970246A2 (en) 1998-04-30
TNSN97085A1 (en) 2005-03-15
YU18797A (en) 1999-11-22
CO4990925A1 (en) 2000-12-26
EP0912487A1 (en) 1999-05-06
ID20291A (en) 1998-11-19
HRP970246B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
ZA977700B (en) Phosphinic acid amides as matrix metalloprotease inhibitors.
TR199501472A2 (en) Matrix metalloprotease inhibitors.
IL128663A0 (en) 1,4-heterocyclic metalloprotease inhibitors
IL128661A0 (en) 1,3-diheterocyclic metalloprotease inhibitors
ZA9811794B (en) Ace inhibitor-MMP inhibitor combinations.
AU8858398A (en) Matrix metalloproteinase inhibitors
ZA96850B (en) Matrix metalloprotease inhibitors.
PL349025A1 (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
ZA975631B (en) Matrix metalloproteinase inhibitors.
ZA979756B (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors.
ZA974030B (en) Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids.
ZA978307B (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase.
IL137162A0 (en) 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
PL342763A1 (en) Matrix metaloprotease inhibitor
IL115995A0 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
ZA974033B (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors.
ZA974032B (en) Substituted oxobutyric acids as matrix metalloproteinases inhibitors.
HRP970245B1 (en) Biaryl acetilenes as matrix metalloprotease inhibitors
ZA974028B (en) Inhibition of matrix metalloproteinases by 2(w-aroylalkyl)-4-biaryl-4-oxobutyric acids.
AU9747098A (en) Aporphinoid matrix metalloproteinase inhibitors
AU3534195A (en) Aldehyde derivatives as upsteine protease inhibitors
ZA977916B (en) Method of inhibiting matrix metalloproteinases.
SI0901466T1 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
SI0928291T1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
ZA979457B (en) Substituted gamma aminobutyric acids as pharmaceutical agents.